Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
- VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
- Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
- Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
- “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.